The RANK/RANKL/OPG triad in cancer-induced bone diseases
- PMID: 17180711
- DOI: 10.1007/s10555-006-9021-3
The RANK/RANKL/OPG triad in cancer-induced bone diseases
Abstract
The maintenance of skeletal integrity in a healthy individual requires a balanced regulation of the processes of bone formation, mediated by osteoblasts, and bone resorption, mediated by osteoclasts. This balanced process of bone remodeling becomes co-opted in the skeleton by tumor cells and this dramatically accelerates the process of remodeling and disrupts the normal equilibrium resulting in a spectrum of osteolytic to osteoblastic bone lesions. Certain tumor types, such as breast and prostate, frequently metastasize to the bone. It is now widely understood that the molecular triad--receptor activator of NF-kappaB ligand (RANKL), its receptor RANK, and the endogenous soluble RANKL inhibitor, osteoprotegerin (OPG)--play direct and essential roles in the formation, function, and survival of osteoclasts. Osteoclastic bone resorption contributes to the majority of skeletal sequelae, or skeletal-related events (SREs), in patients with bone metastases. In addition, osteoclastic bone resorption also contributes to the establishment of tumors in the skeleton. Therefore, blocking osteoclast activity and differentiation via RANKL inhibition may not only provide a beneficial treatment for skeletal complications of malignancy, but may also prevent bone metastases. In this review, we will first describe the operative role of osteoclasts and the RANK/RANKL/OPG triad in the pathophysiology of cancer-induced bone diseases, specifically solid tumor metastases to the bone. Secondly, we will describe a therapeutic approach that specifically targets the RANKL molecule.
Similar articles
-
RANKL signaling in bone physiology and cancer.Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be. Curr Opin Support Palliat Care. 2007. PMID: 18685382 Review.
-
DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.Bone. 2007 Apr;40(4):981-90. doi: 10.1016/j.bone.2006.11.006. Epub 2006 Dec 28. Bone. 2007. PMID: 17196895
-
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.Prostate. 2008 Jan 1;68(1):92-104. doi: 10.1002/pros.20678. Prostate. 2008. PMID: 18008334
-
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.Bone. 2007 Aug;41(2):165-74. doi: 10.1016/j.bone.2007.04.190. Epub 2007 May 5. Bone. 2007. PMID: 17560185
-
RANK ligand as a therapeutic target for bone metastases and multiple myeloma.Cancer Treat Rev. 2008 Feb;34(1):92-101. doi: 10.1016/j.ctrv.2007.09.002. Epub 2007 Oct 26. Cancer Treat Rev. 2008. PMID: 17964729 Review.
Cited by
-
Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease.Chin Med J (Engl). 2016 Jul 20;129(14):1696-703. doi: 10.4103/0366-6999.185857. Chin Med J (Engl). 2016. PMID: 27411457 Free PMC article.
-
Exploration of the Effect of Icariin on Nude Mice with Lung Cancer Bone Metastasis via the OPG/RANKL/RANK System.Comput Math Methods Med. 2022 May 28;2022:2011625. doi: 10.1155/2022/2011625. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Jun 28;2023:9865158. doi: 10.1155/2023/9865158. PMID: 35669373 Free PMC article. Retracted.
-
Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications.Indian J Endocrinol Metab. 2011 Jul;15(3):175-81. doi: 10.4103/2230-8210.83401. Indian J Endocrinol Metab. 2011. PMID: 21897893 Free PMC article.
-
VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL.Oncol Res. 2009;18(2-3):117-25. doi: 10.3727/096504009789954627. Oncol Res. 2009. PMID: 20066901 Free PMC article.
-
Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.Transl Oncol. 2022 Nov;25:101532. doi: 10.1016/j.tranon.2022.101532. Epub 2022 Sep 11. Transl Oncol. 2022. PMID: 36103755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical